AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02016417 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: A combination of Docetaxel, cisplatin and 5-Fluorouracil
Description: The TPF regimen consists of docetaxel at a dose of 60 mg/m2/day on day 1, cisplatin 60 mg/m2 by i.v. infusion for 4 h on day 1-3, plus 5-Fluorouracil 600 mg/m2 CIV over 120 hours. The regime will be repeated every 3 weeks up to a total of 2-3 courses. Concurrent chemoradiotherapy is administrated with 3 cycles of weekly Cisplatin 100 mg/m2 starting on the first day of IMRT.
Study NCT03691623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP-938 Dose 1
Description: Oral suspension for 5 days
Study NCT03691623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP-938 Dose 2
Description: Oral suspension for 5 days
Study NCT00117442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Chemotherapy
Study NCT03691623 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral suspension for 5 days
Study NCT03691623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP-938 Dose 3
Description: Oral suspension for 5 days
Study NCT03691623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP-938 Dose 4
Description: Oral suspension for 5 days
Study NCT04187222 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Mechanical debridements
Description: Prior to the beginning of the intervention, all patients received oral hygiene instruction. Mechanical debridements were performed with titanium curette and polishing using a rubber bowl and polishing paste.
Study NCT04187222 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mechanical debridements
Description: Prior to the beginning of the intervention, all patients received oral hygiene instruction. Mechanical debridements were performed with titanium curette and polishing using a rubber bowl and polishing paste.
Study NCT04187222 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bifidobacterium animalis subsp. lactis
Description: Capsules containing Bifidobacterium animalis subsp. lactis were chubby and subsequently ingested twice a day for 12 weeks.
Study NCT01740622 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Injury Prevention Measures
Description: The hazards identified in the home will be reviewed with the parent and the proposed interventions will be presented. Intervention options are designed and prioritized so that the most passive and durable interventions are recommended first (e.g. self-closing, self-locking stair gate) and progressively less 'passive' and less durable options last (e.g. area gate, pressure mounted gate, or refusal of intervention).
Study NCT02998008 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: high intensity interval training
Study NCT01809262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: single dose of 5 mcg
Description: solution for inhalation
Study NCT00117442 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: chemotherapy
Study NCT00117442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: chemotherapy
Study NCT00117442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegfilgrastim
Description: Growth factor for mobilization
Study NCT01809262 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: single dose of placebo
Description: solution for inhalation
Study NCT01809262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: single dose of 40 mcg
Description: solution for inhalation
Study NCT01809262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: single dose of 20 mcg
Description: solution for inhalation
Study NCT01809262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: single dose of 2 mcg
Description: solution for inhalation
Study NCT01809262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: single dose of 10 mcg
Description: solution for inhalation
Study NCT02773758 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stannous Fluoride Dentifrice
Description: Experimental dentifrice containing 0.454%w/w stannous fluoride (1100ppm fluoride)
Study NCT02773758 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Sodium monofluorophosphate Dentifrice
Description: Dentifrice containing 0.76% w/w sodium monofluorophosphate (1000ppm fluoride)
Study NCT05159232 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hospital stay
Description: hospital stay in in inguinal hernia repair
Study NCT00637273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide once weekly
Description: subcutaneous injection, 2.0mg, once a week
Study NCT00637273 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sitagliptin
Description: oral tablet, 100mg, once a day
Study NCT00637273 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pioglitazone
Description: oral tablet, 45mg, once a day
Study NCT00637273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo tablet
Description: oral tablet, once a day
Study NCT00637273 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo once weekly
Description: subcutaneous injection, once a week
Study NCT01279135 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Radiation
Description: Standard Pelvic Radiation 50 Gy/ 25 fractions over 5 weeks
Study NCT01279135 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Tomotherapy based IGRT
Description: Patients in this arm will received Tomotherapy based Image Guided Intensity Modulated Radiotherapy to a dose of 50 Gy/25 fractions/5 weeks
Study NCT01798706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lixisenatide (AVE0010)
Description: Pharmaceutical form: Solution for injection in pre-filled pen administered 30 to 60 minutes before breakfast in the morning~Route of administration: Subcutaneous injection
Study NCT01798706 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: Solution for injection in pre-filled pen administered 30 to 60 minutes before breakfast in the morning~Route of administration: Subcutaneous injection
Study NCT01798706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antidiabetic background therapy
Description: Participants received a stable regimen of anti-diabetic background therapy for at least 3 months prior to screening, during the placebo run-in period and the 24 week treatment period. Allowed background antidiabetic therapy included metformin, sulfonylurea (except glibenclamide >10 mg, gliclazide >160 mg), meglitinides (except repaglinide >6 mg), pioglitazone and basal insulin. Insulin glargine, neutral protamine hagedorn (NPH) insulin, detemir, lente and ultralente were considered as basal insulin.
Study NCT01798706 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Antidiabetic background therapy
Description: Participants received a stable regimen of anti-diabetic background therapy for at least 3 months prior to screening, during the placebo run-in period and the 24 week treatment period. Allowed background antidiabetic therapy included metformin, sulfonylurea (except glibenclamide >10 mg, gliclazide >160 mg), meglitinides (except repaglinide >6 mg), pioglitazone and basal insulin. Insulin glargine, neutral protamine hagedorn (NPH) insulin, detemir, lente and ultralente were considered as basal insulin.
Study NCT03797950 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Voice Reminder (Group A)
Description: Woman with a recent delivery will be contacted via mobile phone by a central study staff member to encourage them to vaccinate their newborn with OPV0 and BCG, and information on where and when vaccines are available in this community will be provided. Community volunteers will receive small incentives for documenting births in the community.
Study NCT03797950 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cash Incentive (Group B)
Description: Mobile phone based monetary incentives will be provided to community volunteers and to women with a recent delivery who vaccinate newborns with OPV0 and BCG on time. Community volunteers will receive small incentives for documenting births in the community.
Study NCT00824486 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Injury prevention education (TIPP)
Description: using TIPP materials
Study NCT00824486 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Injury prevention education (safe home)
Description: using safe home model
Study NCT03637842 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lorcaserin
Description: Lorcaserin XR 20mg per day
Study NCT03637842 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo
Study NCT03736083 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Freestyle Libre Blood Glucose Monitor
Description: The intervention arm of this study will begin using the Freestyle Libre glucose monitor within 2 weeks of their diabetes diagnosis
Study NCT04126369 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mindfulness intervention
Description: The mindfulness program is conducted in a group session of up to 10 people. Each session lasts 2 hours. A total of 12 sessions will be conducted by a practitioner who is specifically trained in this type of programme.
Study NCT04126369 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: psycho educative programme
Description: The psycho-educational control intervention will follow the same format and structure as the mindfulness meditation intervention in terms of group format, session duration and frequency. This is a therapeutic education programme developed for several years in the neurology department of the university hospital of Lyon and Grenoble. The program follows the repository recommended by the french league against epilepsy.
Study NCT02682888 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: trait anxiety scale
Description: splitting subjects into 2 groups according to scores of the trait anxiety scale
Study NCT02682888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: intranasal administration of oxytocin
Study NCT04349371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine
Description: Subjects will take two tabs of 250mg for every day for one week and then two tabs of 250mg for 1 day a week thereafter for study duration of 3 months). Subjects with severe GI intolerance can take 1 tablet of 250mg daily for the first week and 1 tablet per week for the remainder of the 3 month study duration.
Study NCT04349371 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Subjects will take two tabs of placebo for every day for one week and then two tabs of placebo for 1 day a week thereafter for study duration of 3 months).
Study NCT00760305 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pro self pain control programme
Description: A 6 week psychoeducational programme that included three home visits and three phone calls. Patients were taught about pain medication and side effects and about incorrect information regarding cancer pain management
Study NCT01855503 — intervention group
Intervention type: PROCEDURE
Intervention: Core Biopsy
Study NCT02787174 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Asthma Medication Adherence Education
Study NCT03485885 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Standardized maqui berry extract enriched in anthocyanins
Description: Single oral intake of 1000mg standardized maqui berry extract (in 4 capsules - 250mg each) with 200ml still water
Study NCT03731455 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WISE Cortical Strip
Description: The WISE Cortical Strip is a medical device composed by a strip and by a cable.
Study NCT01707446 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cerebral oximetry monitor (The INVOS® Cerebral/Somatic Oximeter)
Description: In the intervention group, an alarm threshold at 75% of the baseline rSO2 value will be established. Based on predetermined algorithm the rSO2 will be maintained at or above 75% of the baseline measurements.
Study NCT01707446 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: An alarm threshold at 75% of the baseline rSO2 value
Description: If the threshold of \< 75% from baseline is reached for > 1 minute an algorithm geared to restore rSO2 to baseline levels will be implemented.
Study NCT03138382 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vestibular Nerve Stimulator
Description: Electrical stimulation of the vestibular nerve with vestibular nerve stimulator (GVS device) for for 45 minutes using binaural mastoid placement.
Study NCT03138382 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham stimulator
Description: Looks identical to vestibular nerve stimulator but discharges current into an internal resistor rather than activating the vestibular nerves.
Study NCT02423954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Study NCT02423954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Study NCT02423954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan + capecitabine
Study NCT02423954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab
Study NCT03016702 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive stress tests during functional MRI
Description: Subjects will undergo progressively more complex cognitive stress tests that assess memory and executive function while undergoing fMRI.
Study NCT03486496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gefitinib
Description: Patients will be treated with gefitinib, 250 mg p.o., daily
Study NCT03486496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berberine
Description: Patients will be treated with Berberine, 50 mg p.o., tid
Study NCT03563443 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Genomic Imprinting Testing
Description: The changes of LOI The obtained LOI from morning urine and tumor will be tested by LiSen imprinting diagnostic (LSID)
Study NCT03369496 — intervention group
Intervention type: OTHER
Intervention: Social capital; Neighborhood environment
Description: Observational study examining the relationship among neighborhood environment, social capital and health among Montreal adults
Study NCT00935805 — intervention group
Intervention type: DRUG
Intervention: Metformin
Description: 850 mg TID
Study NCT00935805 — intervention group
Intervention type: DRUG
Intervention: Glybenclamide
Description: 10 mg BID
Study NCT00935805 — intervention group
Intervention type: DRUG
Intervention: NPH insulin
Description: Variable SC dose
Study NCT00935805 — intervention group
Intervention type: DRUG
Intervention: Hydrochlorothiazide
Description: 25 mg QD introduced as initial therapy for hypertension
Study NCT00935805 — intervention group
Intervention type: DRUG
Intervention: Propranolol
Description: 40 mg BID
Study NCT00935805 — intervention group
Intervention type: DRUG
Intervention: Captopril
Description: 50 mg TID
Study NCT00935805 — intervention group
Intervention type: DRUG
Intervention: Amlodipine
Description: 10 mg QD
Study NCT03690349 — intervention group
Intervention type: OTHER
Intervention: Skin test
Description: Demographic data review, Disease severity evaluation, Treatment evaluation and Skin prick test for 16 common aeroallergens
Study NCT00000380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GHRH
Study NCT00000380 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GHRH
Study NCT03806491 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia
Description: Study therapists will follow the 2014 CBT-I in Veterans manual developed by leading researchers in the behavioral sleep medicine field. Intervention components include (1) sleep hygiene: limiting naps; avoiding caffeine, tobacco, alcohol, and rich/heavy foods before bedtime; exercising; establishing a bedtime routine; and creating a comfortable sleep environment; (2) sleep restriction: limiting time in bed in order to improve sleep efficiency, or the percentage of time in bed that is actually spent sleeping; time in bed will be titrated each week based on sleep efficiency; (3) stimulus control: strengthening association between bedroom and sleep to decrease conditioned arousal; (4) relaxation: diaphragmatic breathing, progressive muscle relaxation, and visual imagery to reduce arousal; and (5) cognitive therapy: identifying and challenging thoughts that interfere with sleep.
Study NCT03806491 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Hygiene
Description: Study therapists will review a one-page handout on sleep hygiene with all participants. This is the only intervention that participants assigned to the sleep hygiene condition will receive. This is consistent with what may be expected as standard care in a doctor's visit with a primary care physician.
Study NCT03806491 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alcohol Use Disorder Treatment as Usual
Description: CBT-based groups for Alcohol Use Disorder will focus on the acquisition of skills needed to cope effectively with urges and cravings to drink and manage high-risk situations.
Study NCT03806491 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol Use Disorder Treatment as Usual
Description: CBT-based groups for Alcohol Use Disorder will focus on the acquisition of skills needed to cope effectively with urges and cravings to drink and manage high-risk situations.
Study NCT02837913 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: VitaHeat underbody heating mattress
Description: Use of VitaHeat underbody heating mattress will be used for the intervention arm to reduce hypothermia post operatively
Study NCT02837913 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VitaHeat underbody heating mattress
Description: Use of VitaHeat underbody heating mattress will be used for the intervention arm to reduce hypothermia post operatively
Study NCT02682888 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intranasal administration of placebo
Study NCT03900013 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Injectable platelet rich fibrin combined with DFDBA
Description: The i-PRF will be mixed with bone graft then will be placed into the intraosseous defect
Study NCT03900013 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Demineralized Freeze Dried Bone Allograft
Description: Demineralized Freeze Dried Bone Allograft alone will be placed into the intraosseous defect
Study NCT01532908 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MBL-HCV1
Description: 50 mg/kg MBL-HCV1, intravenous, up to 15 infusions over 56 days; option for extended treatment through 84 days if viral load undetectable at day 56
Study NCT01657032 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Smectite
Description: Eligible children received smectite (3g) once a day till diarrhea stop with LGG (ATCC 53103) at a daily dosage of 6×10 9 colony forming units (CFU) in one dose for 7 days.
Study NCT03555279 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PHAT Life: Preventing HIV/AIDS Among Teens--PS Arm
Description: HIV Prevention Behavioral Health Intervention delivered by Probation Staff
Study NCT01657032 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Eligible children received placebo: glucose (3g) once a day till diarrhea stop with LGG (ATCC 53103) at a daily dosage of 6×10 9 colony forming units (CFU) in one dose for 7 days.
Study NCT01657032 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Lactobacillus GG
Description: All children received LGG (ATCC 53103), dose 6×10 9 colony forming units (CFU), once a day for 7 days with placebo or smectite
Study NCT03555279 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PHAT Life: Preventing HIV/AIDS Among Teens--YR Arm
Description: HIV Prevention Behavioral Health Intervention delivered by Youth Representatives
Study NCT01657032 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus GG
Description: All children received LGG (ATCC 53103), dose 6×10 9 colony forming units (CFU), once a day for 7 days with placebo or smectite
Study NCT01333761 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiox FDS
Description: The Cardiox Shunt Detection system consists of a sensor placed in contact with the outer ear, similar to a finger probe used to detect oxygen levels in blood. Through an intravenous line, ICG (indocyanine green) at a dosage of 10 mg (2 mL of 5 mg/mL ICG solution) per test, is administered into the right or left antecubital fossa. The presence of ICG in the veins within the outer ear are detected, and the results are displayed on a monitor. All patients will also be evaluated with TCD and TEE for the presence of RTLS.
Study NCT01710228 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: methylprednisolone
Description: 192 MG FOR 5 CONSECUTIVE DAYS EVERY 4 WEEKS FOR 10 MONTHS
Study NCT01710228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: 192 MG FOR 5 CONSECUTIVE DAYS EVERY 4 WEEKS FOR 10 MONTHS
Study NCT04420481 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Somatropin
Description: Dose: 1,4 mg (4,2 IE) every other day Dosage: 9 month treatment period and a 3 month follow-up period Administration: One subcutaneous injection of somatropin or corresponding placebo in the thigh or abdomen given in the evening given every other day.